1. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease / N. Abdel-Wahab, M. Shah, M.A. Lopez-Olivo, M.E. SuarezAlmazor // Ann Intern Med. ‒ 2018. ‒ Vol. 169, No 2. ‒ P. 133-134. ‒ DOI: 10.7326/l18-0209. 2. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis / R. Barroso-Sousa, W.T. Barry, 59 A.C. Garrido-Castro [et al.] // JAMA Oncol. ‒ 2018. ‒ Vol. 4, No 2. ‒ P. 173-182. ‒ DOI: 10.1001/jamaoncol.2017.3064. 3. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями / С. А. Проценко, Н. Ю. Антимоник, М. Ф. Баллюзек [и др.] // Злокачественные опухоли: Практические рекомендации RUSSCO ‒2022. ‒ T. 12. ‒ № 3s2. ‒ C. 203-241. ‒ DOI 10.18027/2224-5057-2021-11-3s2-50. 4. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. / W.-W. Chen, A. Razak, P. L Bedard [et al.] 2015. . 5. ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors / A. Yang, S. Baxi, D. Korenstein // J Oncol Pract. ‒ 2018. ‒ Vol. 14, No 2. ‒ P. 72-76. ‒ DOI: 10.1200/jop.2017.025114. 6. SERVICES U. S. D. O. H. A. H. - Common Terminology Criteria for Adverse Events (CTCAE) Version 5. - 2017. - 155 p. 7. Management of Immunotherapy-Related Toxicities, Version 1.2022 / J.A. Thompson, B.J. Schneider, J. Brahmer [et al.] // J Natl Compr Canc Netw. ‒ 2022. ‒ Vol. 20, No 4. ‒ P. 387-405. ‒ DOI: 10.6004/jnccn.2022.0020. 8. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis / D.Y. Wang, J.E. Salem, J.V. Cohen [et al.] // JAMA Oncol. ‒ 2018. ‒ Vol. 4, No 12. ‒ P. 1721-1728. ‒ DOI: 10.1001/jamaoncol.2018.3923. 9. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / J. Haanen, F. Carbonnel, C. Robert [et al.] // Ann Oncol. ‒ 2017. ‒ Vol. 28, No suppl_4. ‒ P. iv119-iv142. ‒ DOI: 10.1093/annonc/mdx225. 10. Population-based assessment of adverse events associated with long-term glucocorticoid use / J.R. Curtis, A.O. Westfall, J. Allison [et al.] // Arthritis Rheum. ‒ 2006. ‒ Vol. 55, No 3. ‒ P. 420-6. ‒ DOI: 10.1002/art.21984. 11. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations / S. Mori, S. Fujiyama // World J Gastroenterol. ‒ 2015. ‒ Vol. 21, No 36. ‒ P. 10274-89. ‒ DOI: 10.3748/wjg.v21.i36.10274. 12. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab / A.M. Menzies, D.B. Johnson, S. Ramanujam [et al.] // Ann Oncol. ‒ 2017. ‒ Vol. 28, No 2. ‒ P. 368-376. ‒ DOI: 10.1093/annonc/mdw443. 13. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders / D.B. Johnson, R.J. Sullivan, P.A. Ott [et al.] // JAMA Oncol. ‒ 2016. ‒ Vol. 2, No 2. ‒ P. 234-40. ‒ DOI: 10.1001/jamaoncol.2015.4368. 60 14. NCCN. Management of Immunjtherapy-related toxicities (version 1.2023). ‒ 2023 [electronic resource]. ‒ URL: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf (дата обращения: 02.05.2023). 15. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy / M.L. Manzano-Alonso, G. Castellano-Tortajada // World J Gastroenterol. ‒ 2011. ‒ Vol. 17, No 12. ‒ P. 1531-7. ‒ DOI: 10.3748/wjg.v17.i12. 1531. 16. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. / L. Zimmer, S. Goldinger, L. Hofmann [et al.] 2016. . 17. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature / S. Cuzzubbo, F. Javeri, M. Tissier [et al.] // Eur J Cancer. ‒ 2017. ‒ Vol. 73. ‒ P. 1-8. ‒ DOI: 10.1016/j.ejca.2016.12.001. 18. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity / R. Gutzmer, A. Koop, F. Meier [et al.] // Eur J Cancer. ‒ 2017. ‒ Vol. 75. ‒ P. 24-32. ‒ DOI: 10.1016/j.ejca.2016.12.038. 19. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis / P. Tandon, S. Bourassa-Blanchette, K. Bishay [et al.] // J Immunother. ‒ 2018. ‒ Vol. 41, No 3. ‒ P. 101-108. ‒ DOI: 10.1097/cji.0000000000000213. 20. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors / P. Cramer, R.S. Bresalier // Curr Gastroenterol Rep. ‒ 2017. ‒ Vol. 19, No 1. ‒ P. 3. ‒ DOI: 10.1007/s11894-017-0540-6. 21. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy / L. Hofmann, A. Forschner, C. Loquai [et al.] // Eur J Cancer. ‒ 2016. ‒ Vol. 60. ‒ P. 190-209. ‒ DOI: 10.1016/j.ejca.2016.02.025. 22. Endocrinological side-effects of immune checkpoint inhibitors / F. Torino, S.M. Corsello, R. Salvatori // Curr Opin Oncol. ‒ 2016. ‒ Vol. 28, No 4. ‒ P. 278-87. ‒ DOI: 10.1097/cco.0000000000000293. 23. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors / E. De Martin, J.M. Michot, B. Papouin [et al.] // J Hepatol. ‒ 2018. ‒ Vol. 68, No 6. ‒ P. 1181-1190. ‒ DOI: 10.1016/j.jhep.2018.01.033. 24. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis / A. Bertrand, M. Kostine, T. Barnetche [et al.] // BMC Med. ‒ 2015. ‒ Vol. 13. ‒ P. 211. ‒ DOI: 10.1186/s12916-015-0455-8. 61 25. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials / M. Khunger, S. Rakshit, V. Pasupuleti [et al.] // Chest. ‒ 2017. ‒ Vol. 152, No 2. ‒ P. 271-281. ‒ DOI: 10.1016/j.chest.2017.04.177. 26. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management / S. Grover, O.E. Rahma, N. Hashemi, R.M. Lim // American Society of Clinical Oncology Educational Book. ‒ 2018.10.1200/edbk_100013, No 38. ‒ P. 13-19. ‒ DOI: 10.1200/edbk_100013. 27. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management / B.M. Huffman, L.A. Kottschade, P.S. Kamath, S.N. Markovic // Am J Clin Oncol. ‒ 2018. ‒ Vol. 41, No 8. ‒ P. 760-765. ‒ DOI: 10.1097/coc.0000000000000374. 28. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy / V. Sibaud // Am J Clin Dermatol. ‒ 2018. ‒ Vol. 19, No 3. ‒ P. 345-361. ‒ DOI: 10.1007/s40257-017-0336-3. 29. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review / L. Khoja, D. Day, T. Wei-Wu Chen [et al.] // Ann Oncol. ‒ 2017. ‒ Vol. 28, No 10. ‒ P. 2377-2385. ‒ DOI: 10.1093/annonc/mdx286. 30. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy / V. Kumar, N. Chaudhary, M. Garg [et al.] // Front Pharmacol. ‒ 2017. ‒ Vol. 8. ‒ P. 49. ‒ DOI: 10.3389/fphar.2017.00049. 31. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline / J.R. Brahmer, C. Lacchetti, B.J. Schneider [et al.] // J Clin Oncol. ‒ 2018. ‒ Vol. 36, No 17. ‒ P. 1714-1768. ‒ DOI: 10.1200/jco.2017.77.6385. 32. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis / V. Bergqvist, E. Hertervig, P. Gedeon [et al.] // Cancer Immunol Immunother. ‒ 2017. ‒ Vol. 66, No 5. ‒ P. 581-592. ‒ DOI: 10.1007/s00262-017-1962-6. 33. Systematic review: colitis associated with anti-CTLA-4 therapy / A. Gupta, K.M. De Felice, E.V. Loftus, Jr., S. Khanna // Aliment Pharmacol Ther. ‒ 2015. ‒ Vol. 42, No 4. ‒ P. 406-17. ‒ DOI: 10.1111/apt.13281. 34. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies / D.J. Byun, J.D. Wolchok, L.M. Rosenberg, M. Girotra // Nat Rev Endocrinol. ‒ 2017. ‒ Vol. 13, No 4. ‒ P. 195-207. ‒ DOI: 10.1038/nrendo.2016.205. 62 35. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitorrelated pneumonitis / S. Chuzi, F. Tavora, M. Cruz [et al.] // Cancer Manag Res. ‒ 2017. ‒ Vol. 9. ‒ P. 207-213. ‒ DOI: 10.2147/cmar.s136818. 36. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis / M. Nishino, A. Giobbie-Hurder, H. Hatabu [et al.] // JAMA Oncol. ‒ 2016. ‒ Vol. 2, No 12. ‒ P. 1607-1616. ‒ DOI: 10.1001/jamaoncol.2016.2453. 37. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia / J.C. Fitzgerald, S.L. Weiss, S.L. Maude [et al.] // Crit Care Med. ‒ 2017. ‒ Vol. 45, No 2. ‒ P. e124-e131. ‒ DOI: 10.1097/ccm.0000000000002053. 38. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia / N.V. Frey, D.L. Porter // Hematology Am Soc Hematol Educ Program. ‒ 2016. ‒ Vol. 2016, No 1. ‒ P. 567-572. ‒ DOI: 10.1182/asheducation-2016.1.567. 39. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy / K.A. Hay, L.A. Hanafi, D. Li [et al.] // Blood. ‒ 2017. ‒ Vol. 130, No 21. ‒ P. 2295-2306. ‒ DOI: 10.1182/blood-2017-06-793141. 40. Current concepts in the diagnosis and management of cytokine release syndrome / D.W. Lee, R. Gardner, D.L. Porter [et al.] // Blood. ‒ 2014. ‒ Vol. 124, No 2. ‒ P. 188-95. ‒ DOI: 10.1182/blood-2014-05-552729. 41. Autoimmune hepatitis / G. Mieli-Vergani, D. Vergani, A.J. Czaja [et al.] // Nat Rev Dis Primers. ‒ 2018. ‒ Vol. 4. ‒ P. 18017. ‒ DOI: 10.1038/nrdp.2018.17. 42. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma / J. Weber, J.A. Thompson, O. Hamid [et al.] // Clin Cancer Res. ‒ 2009. ‒ Vol. 15, No 17. ‒ P. 5591-8. ‒ DOI: 10.1158/1078-0432.ccr-09-1024. 43. Сравнительный анализ эффективности и безопасности фторированных и хлорированных топических глюкокортикостероидов / Свирщевская Е.В., Матушевская Е.В. // Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. ‒ 2010. ‒ T. 3, № 3. ‒ C. 76-80. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report / M. Brunet, T. van Gelder, A. Asberg [et al.] // Ther Drug Monit. ‒ 2019. ‒ Vol. 41. ‒ No 3. ‒ P. 261-307. ‒ DOI 10.1097/FTD.0000000000000640. 45. The use of tacrolimus in the management of checkpoint inhibitor immunotherapy-induced hepatitis / S. McIlwaine, A. Cullen, L. Stratton [et al.] // Journal of the Royal College of 63 Physicians of Edinburgh. ‒ 2022. ‒ Vol. 52. ‒ No 1. ‒ P. 20-23. ‒ DOI 10.1177/14782715221088911. 46. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab / R. L. Johnston, J. Lutzky, A. Chodhry, J. S. Barkin// Dig Dis Sci. ‒ 2009. ‒ Vol. 54. ‒ No 11. ‒ P. 2538-40. ‒ DOI 10.1007/s10620-008-0641-z. 47. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients / C. J. Turtle, L. A. Hanafi, C. Berger [et al.] // J Clin Invest. ‒ 2016. ‒ Vol. 126. ‒ No 6. ‒ P. 2123-38. ‒ DOI 10.1172/jci85309. 48. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date / J. H. Park, M. B. Geyer, R. J. Brentjens// Blood. ‒ 2016. ‒ Vol. 127. ‒ No 26. ‒ P. 3312-20. ‒ DOI 10.1182/blood-2016-02-629063. 49. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance / A. Mascolo, C. Scavone, C. Ferrajolo [et al.] // Drug Saf. ‒ 2021.10.1007/s40264-021-01086-8. ‒ DOI 10.1007/s40264-021-01086-8. 50. Cardiotoxicity associated with immune checkpoint inhibitors therapy: A meta-analysis / N. Rubio-Infante, Y. A. Ramírez-Flores, E. C. Castillo [et al.] // Eur J Heart Fail. ‒ 2021.10.1002/ejhf.2289. ‒ DOI 10.1002/ejhf.2289. 51. Progress in Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Cardiotoxicity / F. Wang, S. Qin// J Cancer Immunol. ‒ 2020. ‒ Vol. 2. ‒ No 3. ‒ P. 96-102. 52. Increased soluble programed cell death-ligand 1 is associated with acute coronary syndrome / K. Fujisue, E. Yamamoto, D. Sueta [et al.] // Int J Cardiol. ‒ 2022. ‒ Vol. 349. ‒ P. 1-6. ‒ DOI 10.1016/j.ijcard.2021.11.060. 53. Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports / E. A. Alghamdi, H. Aljohani, W. Alghamdi, F. Alharbi// Saudi Pharm J. ‒ 2022. ‒ Vol. 30. ‒ No 8. ‒ P. 1193-1199. ‒ DOI 10.1016/j.jsps.2022.06.010. 54. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review / R. Wanchoo, S. Karam, N. N. Uppal [et al.] // Am J Nephrol. ‒ 2017. ‒ Vol. 45. ‒ No 2. ‒ P. 160-169. ‒ DOI 10.1159/000455014. 55. Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP / G. Folprecht, K. Trautmann, A. Stein [et al.] // Br J Cancer. ‒ 2021. ‒ Vol. 124. ‒ No 4. ‒ P. 721-727. ‒ DOI 10.1038/s41416-020-01141-8.